Institut Jules Bordet, Brussels, Belgium.
Expert Opin Investig Drugs. 2010 Apr;19 Suppl 1:S31-9. doi: 10.1517/13543781003730135.
Trastuzumab is now considered the standard of care for the adjuvant treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer patients, yet a sizable number of HER2-positive patients do not benefit from this treatment. For patients who progress on or after completion of adjuvant trastuzumab therapy, the standard of care is uncertain. Newer tyrosine kinase inhibitors and monoclonal antibodies are being evaluated in clinical trials for optimisation of treatment in this group. The interplay of HER2 and hormonal signalling pathways is being manipulated to see if response rates can be bettered. In this reveiw we explain the present role of the new molecules with a case scenario. The new anti-HER2 drugs have the potential to change clinical practise of targeting HER2 in the future. Better understanding of HER2 functions and interactions of different signalling pathways will be essential for optimal targetted therapies.
曲妥珠单抗现在被认为是人表皮生长因子受体-2（HER2）阳性乳腺癌患者辅助治疗的标准治疗方法，但仍有相当数量的 HER2 阳性患者不能从中受益。对于在辅助曲妥珠单抗治疗期间或之后进展的患者，标准治疗方法尚不确定。在临床试验中，正在评估新型酪氨酸激酶抑制剂和单克隆抗体，以优化这组患者的治疗。目前正在对 HER2 和激素信号通路的相互作用进行研究，以观察是否可以提高缓解率。在本综述中，我们通过一个病例场景解释了这些新分子的目前作用。新型抗 HER2 药物有可能在未来改变针对 HER2 的临床实践。更好地了解 HER2 的功能和不同信号通路的相互作用对于最佳靶向治疗至关重要。
